IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)		
O'REILLY ET AL.)		
Serial No.:	To be Assigned)	Examiner:	To be assigned
Filed:	Currently Herewith	<i>)</i>	Art Unit:	To be assigned
For:	Endostatin Protein and) Fragments Thereof)		

TRANSMITTAL OF SEQUENCE LISTING UNDER 37 C.F.R. § 1.821(e)

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

According to 37 C.F.R. § 1.821, replacement pages 55-56 are provided that contain the substitute sequence listing. Also provided is a substitute computer readable form that is identical to the substitute paper copy. Pursuant to 37 C.F.R. § 1.821, no new matter pertaining to the sequences as originally filed has been added. Entry of the replacement pages is requested in the Preliminary Amendment enclosed herewith.

Respectfully submitted,

JONES & ASKEW, L.L.P.

By: Lisa C. Elsevier Reg. No. – P44,669

JONES & ASKEW, L.L.P, 2400 Monarch Tower 3424 Peachtree Road, N.E. Atlanta, Georgia 30326 Attorney Docket No. 05213-0640

Express Mail Label No. EL 329860083 US

I hereby certify that this correspondence is being deposited with the United

States Postal Service as Express Mail in an envelope addressed to:

Assistant Commissioner of Patents, Washington, DC 20231, on September 3, 1999.

Lisa C. Elsevier, Reg. No. P-44,669